Therapeutic areas - EleaExeltis

Onco-hematology

Onco-hematology addresses blood cancers such as leukemias, lymphomas, and myelomas—conditions of high clinical complexity within the regional context. At ELEA EXELTIS, we integrate our expertise in oncology and hematology to provide therapeutic solutions focused on these diseases, supporting healthcare professionals across different countries through a specialized and regional approach.

BRAND NAME	ACTIVE INGREDIENT	INDICATION
Alcaf	Carfilzomib	Relapsed or refractory multiple myeloma.
BRAND NAME Alcaf ACTIVE INGREDIENT Carfilzomib INDICATION Relapsed or refractory multiple myeloma. COMMERCIALIZATION
Brocabe	Ibrutinib	Hematologic malignancies (CLL, MCL, MZL), Waldenström macroglobulinemia, and graft-versus-host disease.
BRAND NAME Brocabe ACTIVE INGREDIENT Ibrutinib INDICATION Hematologic malignancies (CLL, MCL, MZL), Waldenström macroglobulinemia, and graft-versus-host disease. COMMERCIALIZATION
Clonomab	Denosumab	An antiresorptive agent for the treatment of metastatic bone disease, giant cell tumor of bone, and hypercalcemia of malignancy.
BRAND NAME Clonomab ACTIVE INGREDIENT Denosumab INDICATION An antiresorptive agent for the treatment of metastatic bone disease, giant cell tumor of bone, and hypercalcemia of malignancy. COMMERCIALIZATION
Novex	Rituximab	Non-Hodgkin lymphoma, CLL, and rheumatoid arthritis.
BRAND NAME Novex ACTIVE INGREDIENT Rituximab INDICATION Non-Hodgkin lymphoma, CLL, and rheumatoid arthritis. COMMERCIALIZATION
Regitrat	Bosutinib	Treatment of PH+ chronic or advanced myelogenous leukemia (CML).
BRAND NAME Regitrat ACTIVE INGREDIENT Bosutinib INDICATION Treatment of PH+ chronic or advanced myelogenous leukemia (CML). COMMERCIALIZATION